Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Analysis

Editor-in-Chief

ISSN (Print): 1573-4129
ISSN (Online): 1875-676X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

A Review on N-nitrosamine Impurity

Author(s): Debangana Pal and Babu B.*

Volume 20, Issue 1, 2024

Published on: 16 January, 2024

Page: [2 - 11] Pages: 10

DOI: 10.2174/0115734129271377231222100236

Price: $65

Open Access Journals Promotions 2
Abstract

Nitrosamines are a category of substances that have a nitroso group linked to an amino group in their molecular structure. They are a category of carcinogens developed as a by-product of drug synthesis and also constituted in the presence of sodium nitrite or nitric acid and secondary amines (like dimethyl amines and diethyl amine) that must be monitored in drug production. In mid-June 2018, the Food and Drug Administration and the European Medicines Agency became aware of the existence of an impurity called N-nitrosamine in some frequently used medications, such as those for blood pressure, antacids, and diabetes. N-nitrosamines are of major concern because the ICH M7 (R1)2 guideline categorizes them as Class 1 impurities or mutagenic carcinogens, and the International Agency for Cancer Research categorizes them as potential carcinogens. The existence of N-nitrosamines in pharmaceutical drugs must be minimized to the greatest extent possible and must be at or below the threshold based on ICH M7(R1)2 fundamentals for materials in the "cohort of concern" described in this guideline and measured based on lifetime constant exposure.

Keywords: NDMA, ICH guidelines, nitrosamines, LCMS/MS, carcinogenic, pharmaceutical drugs.

« Previous Next »
Graphical Abstract

[1]
Bharate, S. Critical analysis of drug product recalls due to nitrosamine impurities. J. Med. Chem., 2021, 64, 2923-2936.
[http://dx.doi.org/10.1021/acs.jmedchem.0c02120]
[2]
Control of nitrosamine impurities in human drugs: Guidance for industry, U.S. Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER). 2020. Available from: https://www.fda.gov/regulatoryinformation/search-fda-guidance-documents/control
[3]
Parr, M.K.; Joseph, J.F. NDMA impurity in valsartan and other pharmaceutical products: Analytical methods for the determination of N-nitrosamines. J. Pharm. Biomed. Anal., 2019, 164, 536-549.
[http://dx.doi.org/10.1016/j.jpba.2018.11.010] [PMID: 30458387]
[4]
US Food and Drug Administration. GC/MS headspace method for detection of NDMA in valsartan drug substance., 2019. Available from: https://www.fda.gov/downloads/Drugs/Drug Safety/UCM618053.pdf
[5]
Seyler, T.H.; Kim, J.G.; Hodgson, J.A.; Cowan, E.A.; Blount, B.C.; Wang, L. Quantitation of urinary volatile nitrosamines from exposure to tobacco smoke. J. Anal. Toxicol., 2013, 37(4), 195-202.
[http://dx.doi.org/10.1093/jat/bkt020] [PMID: 23508653]
[6]
Munch, J.W.; Bassett, M.V. Determination of Nitrosamines in Drinking Water by Solid-phase Extraction and Capillary Column Gas Chromatography with Large Volume Injection and Chemical Ionization Tandem Mass Spectrometry (MS/MS); U. S. Environmental Protection Agency: Cincinnati, Ohio, 2004.
[7]
US Food and Drug Administration. Combined Headspace N-Nitrosodimethylamine (NDMA), N-Nitrosodiethylamine (NDEA), N-Nitrosoethyl isopropyl amine (NEIPA), and N-Nitroso diisopropyl amine (NDIPA) Impurity Assay by GC-MS/MS., 2019. Available from: https://www.fda.gov/media/124025/download
[8]
US FDA updates and press announcements on NDMA in metformin, Available from: https://www.fda.gov/drugs/Drug-safety-and-availability/fda-updates-and-press-announcements-ndma-metformin
[9]
USFDA. FDA updates and press announcements on angiotensin II receptor blocker (ARB) recalls (valsartan, losartan and irbesartan). Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-angiotensin-II-receptor-blocker-arb-recalls-valsartan-losartan (Accessed April. 10, 2020).
[10]
U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Pharmaceutical Quality/Manufacturing Standards/Current Good Manufacturing Practice. 2021. Available from: https://www.fda.gov/media/141720/download (Cited 2021 Apr 8).
[11]
World Health Organization. Essential medicines and health products, information note nitrosamine impurities, update on nitrosamine products., Available from: https://www.who.int/medicines/publications/drugalerts/InformationNote_Nitrosamine-impurities/en/ (Cited 2019 Nov 20).
[12]
US Environmental Protection Agency (EPA). Technical Fact Sheet- NDMA. Washington, DC: US Environmental Protection Agency. Available from: https://www.epa.gov/sites/product/files/2017-10/documents/ndma_fact_sheet_update9-15-17_508.pdf (Cited 2021 Apr 8).
[13]
Usunomena, U.; Ademuyiwa, A.J.; Tinuade, O.O. N-nitrosodimethylamine (NDMA), liver function enzymes, renal function parameters and oxidative stress parameters: A review. Br. J. Pharmacol. Toxicol., 2012, 3(4), 156-176.
[14]
Lin, H.; Hollenberg, P.F. N-nitrosodimethylamine-mediated formation of oxidized and methylated dna bases in a cytochrome P450 2E1 expressing cell line. Chem. Res. Toxicol., 2001, 14(5), 562-566.
[http://dx.doi.org/10.1021/tx0001979] [PMID: 11368555]
[15]
Mirvish, S.S.; Issenberg, P.; Sornson, H.C. Air-water and ether-water distribution of N-nitroso compounds: Implications for laboratory safety, analytic methodology, and carcinogenicity for the rat esophagus, nose, and liver. J. Natl. Cancer Inst., 1976, 56(6), 1125-1129.
[http://dx.doi.org/10.1093/jnci/56.6.1125] [PMID: 994213]
[16]
U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation Research (CBER). M7(R1) assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk, guidance for industry. 2018. Available from: https://www.fda.gov/media/85885/download (Cited 2021 Apr 8).
[17]
White, C.M. Understanding and preventing (N-nitrosodime-thylamine) NDMA contamination of medications. Ann. Pharmacother., 2020, 54(6), 611-614.
[http://dx.doi.org/10.1177/1060028019892222] [PMID: 31771343]
[18]
European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Assessment report, angiotensin-II-receptor antagonists (Sartans) containing tetrazole group. Available from: https://www.ema.europa.eu/en/documents/variation-report/angiotensin-II-receptor-anagonists-sartans-article-31-referral-chmp-assessment-report_en.pdf (Cited Feb 2019).
[19]
Zmyslowski, A N-nitrosodimethylamine contamination in the metformin finished products. Molecules, 2020, 25(22), 1-15.
[http://dx.doi.org/10.3390/molecules25225304]
[20]
Food and Drug Administration. FDA updates and press announcements on NDMA im metformin. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-metformin (Cited 2021 Jul 01).
[21]
Liu, Y.D.; Selbes, M.; Zeng, C.; Zhong, R.; Karanfil, T. Formation mechanism of NDMA from ranitidine, trimethylamine, and other tertiary amines during chloramination: A computational study. Environ. Sci. Technol., 2014, 48(15), 8653-8663.
[http://dx.doi.org/10.1021/es500997e] [PMID: 24968236]
[22]
King, F.J.; Searle, A.D.; Urquhart, M.W. Ranitidine-Investigations into the root cause for the presence of N-nitroso-N, N-dimethylamine in ranitidine hydrochloride drug substances and associated drug products. Org. Process Res. Dev., 2020, 24(12), 2915-2926.
[http://dx.doi.org/10.1021/acs.oprd.0c00462]
[23]
Abe, Y.; Yamamoto, E.; Yoshida, H.; Usui, A.; Tomita, N.; Kanno, H.; Masada, S.; Yokoo, H.; Tsuji, G.; Uchiyama, N.; Hakamatsuka, T.; Demizu, Y.; Izutsu, K.; Goda, Y.; Okuda, H. Temperature-dependent formation of N-nitrosodimethylamine during storage of ranitidine reagent powders and tablets. Chem. Pharm. Bull., 2020, 68(10), 1008-1012.
[http://dx.doi.org/10.1248/cpb.c20-00431] [PMID: 32779580]
[24]
European Medicines Agency. Lessons learnt from the presence N-nitrosamine impurities in Sartan medicines., Available from: https://www.ema.europa.eu/en/documents/other/lessons-learnt-presence-n-nitrosamine-impurities-sartan-medicines-implementation-plan_en.pdf (Cited 2020 Jun 23).
[25]
U.S. Food and Drug Administration. FDA alerts patients and health care professionals to nitrosamine impurity findings in certain metformin extended-release products., Available from: https://www.fda.gov/news-events/press-announcements/fda-alerts-patients-and-health-care-professionals-nitrosamine-impurity-findings-certain-metformin (Cited 2020 May 28).
[26]
Kumar, A.P.V.; Deepa, M. Metformin and nitrosamine impurities. Int. J. Res. Med. Sci., 2020, 8(10), 3778-3784.
[27]
Basel, T.M.; Ohannesian, L.; Streeter, A.J. Handbook of Pharmaceutical Analysis; Marcel Dekker, Inc., 2002.
[28]
Stalikas, C.D. Extraction, separation, and detection methods for phenolic acids and flavonoids. J. Sep. Sci., 2007, 30(18), 3268-3295.
[http://dx.doi.org/10.1002/jssc.200700261] [PMID: 18069740]
[29]
Venkatesan, P.; Valliappan, K. Impurity profiling: Theory and practice. J. Pharm. Sci. Res., 2014, 6, 254-259.
[30]
Ram Parajuli, R.; Pokharel, P.; Bhattarai, M.; Shrestha, B. Impurity profiling: An emerging approach for pharmaceuticals. World J. Pharm. Pharm. Sci., 2018, 7, 1670-1683.
[http://dx.doi.org/10.20959/wjpps20184-11416]
[31]
Qiu, F.; Norwood, D.L. Identification of pharmaceutical impurities. J. Liq. Chromatogr. Relat. Technol., 2007, 30(5-7), 877-935.
[http://dx.doi.org/10.1080/10826070701191151]
[32]
Warad, T.A.; Bhusnure, O.G.; Gholve, S.B. Impurity profile of pharmaceuticals ingredient: A review. J. Pharm. Res., 2016, 10, 523-533.
[33]
Deokate, U.A.; Gorde, A.M. Forced degradation and stability testing: Strategies and analytical perspectives. PharmaTutor, 2014, 2, 61-74.
[34]
Mitch, W.A.; Sharp, J.O.; Trussell, R.R.; Valentine, R.L.; Alvarez-Cohen, L.; Sedlak, D.L. N -Nitrosodimethylamine (NDMA) as a drinking water contaminant: A review. Environ. Eng. Sci., 2003, 20(5), 389-404.
[http://dx.doi.org/10.1089/109287503768335896]
[35]
Liang, Y.; Wang, G.; Xie, L.; Sheng, L. Recent development in liquid chromatography/mass spectrometry and emerging technologies for metabolite identification. Curr. Drug Metab., 2011, 12(4), 329-344.
[http://dx.doi.org/10.2174/138920011795202910] [PMID: 21395529]
[36]
Blanco, M.; Villarroya, I. NIR spectroscopy: A rapid-response analytical tool. TrAC- Trends Anal. Chem., 2002, 21, 24-250.
[37]
Albert, A.; Shelley, J.T.; Engelhard, C. Plasma-based ambient desorption/ionization mass spectrometry: State-of-the-art in qualitative and quantitative analysis. Anal. Bioanal. Chem., 2014, 406(25), 6111-6127.
[http://dx.doi.org/10.1007/s00216-014-7989-z] [PMID: 25069879]
[38]
Serfass, E.J.; Steinhardt, R.G.; Strong, F.C. Classification of quantitative methods of analysis. Anal. Chem., 1950, 22(8), 966-969.
[http://dx.doi.org/10.1021/ac60044a003]
[39]
Trullols, E.; Ruisanchez, I.; Rius, F. X. Validation of qualitative analytical methods. TrAC- Trends Anal. Chem., 2004, 23, 137-145.
[40]
Lee, P.J.; Chen, W.; Gebler, J.C. Qualitative and quantitative analysis of small amine molecules by MALDI-TOF mass spectrometry through charge derivatization. Anal. Chem., 2004, 76(16), 4888-4893.
[http://dx.doi.org/10.1021/ac035537k] [PMID: 15307802]
[41]
Maggio, R.M.; Calvo, N.L.; Vignaduzzo, S.E.; Kaufman, T.S. Pharmaceutical impurities and degradation products: Uses and applications of NMR techniques. J. Pharm. Biomed. Anal., 2014, 101, 102-122.
[http://dx.doi.org/10.1016/j.jpba.2014.04.016] [PMID: 24853620]
[42]
Chandrawanshi, H.K.; Pilaniya, U.; Manchandani, P.; Jain, P.; Singh, N.; Pilaniya, K. Recent trends in the impurity profile of pharmaceuticals. J. Adv. Pharm. Technol. Res., 2010, 1(3), 302-310.
[http://dx.doi.org/10.4103/0110-5558.72422] [PMID: 22247862]
[43]
Shabir, G.A. Validation of high-performance liquid chromatography methods for pharmaceutical analysis: Understanding the differences and similarities between validation requirements of the us food and drug administration. Int. Conf. J. Chromatogr. A., 2003, 987, 57-66.
[44]
Samanidou, V.F. Basic LC method development and optimization. In: Analytical Separation Science; Wiley, 2015.
[http://dx.doi.org/10.1002/9783527678129.assep002]
[45]
Lakka, N.S.; Kuppan, C. Principles of chromatography method development. In: Biochemical Analysis Tools. Methods for Bio-Molecules Studies; Boldura, O.M., Ed.; IntechOpen, 2019.
[http://dx.doi.org/10.5772/intechopen.89501]
[46]
Buszewski, B.; Noga, S. Hydrophilic interaction liquid chromatography (HILIC)--a powerful separation technique. Anal. Bioanal. Chem., 2012, 402(1), 231-247.
[http://dx.doi.org/10.1007/s00216-011-5308-5] [PMID: 21879300]
[47]
Cavazzini, A.; Pasti, L.; Massi, A.; Marchetti, N.; Dondi, F. Recent applications in chiral high performance liquid chromatography: A review. Anal. Chim. Acta, 2011, 706(2), 205-222.
[http://dx.doi.org/10.1016/j.aca.2011.08.038] [PMID: 22023854]
[48]
Coskun, O. Separation tecniques: Chromatography. North. Clin. Istanb., 2016, 3(2), 156-160.
[http://dx.doi.org/10.14744/nci.2016.32757] [PMID: 28058406]
[49]
U.S. Food and Drug Administration. Liquid Chromatography-High Resolution Mass Spectrometry (LC-HRMS) Method for the Determination of NDMA in Ranitidine Drug Substance and Drug Product. 2019. Available from: https://www.fda.gov/media/130801/download (Cited 2019 Sep 13).
[50]
Masada, S.; Tsuji, G.; Arai, R.; Uchiyama, N.; Demizu, Y.; Tsutsumi, T.; Abe, Y.; Akiyama, H.; Hakamatsuka, T.; Izutsu, K.; Goda, Y.; Okuda, H. Rapid and efficient high-performance liquid chromatography analysis of N-nitrosodimethylamine impurity in valsartan drug substance and its products. Sci. Rep., 2019, 9(1), 11852.
[http://dx.doi.org/10.1038/s41598-019-48344-5] [PMID: 31413326]
[51]
Al-Kaseem, M.; Al-Assaf, Z.; Karabeet, F. A rapid, validated RP-HPLC method for the determination of seven volatile N-nitrosamines in meat. Pharmacol. Pharm., 2014, 5(3), 298-308.
[http://dx.doi.org/10.4236/pp.2014.53037]
[52]
Hillebrand, E.; Joshua, H. HPLC Determination of Three N-Nitrosamine Compounds Including N-Nitroso diethanolamine (NDELA) using HPLC with Post-Column Photochemical and Chemical Derivatization. Available from www.aura-inc.com
[53]
Qian, Y.; Wu, M.; Wang, W.; Chen, B.; Zheng, H.; Krasner, S.W.; Hrudey, S.E.; Li, X.F. Determination of 14 nitrosamines at nanogram per liter levels in drinking water. Anal. Chem., 2015, 87(2), 1330-1336.
[http://dx.doi.org/10.1021/ac504104k] [PMID: 25526384]
[54]
Zhao, M.; Li, G.; Kong, W.; Lu, S.; Xia, L.; Chen, G.; Zhao, X.; Wu, Y.; You, J. Convenient and sensitive HPLC method for determination of nitrosamines in foodstuffs based on pre-column fluorescence labeling. Chromatographia, 2016, 79(7-8), 431-439.
[http://dx.doi.org/10.1007/s10337-016-3040-1]
[55]
Bellec, G.; Cauvin, J. M.; Salaun, M. C.; Le CalvA(c), K.; DrA(c)ano, Y.; GouA(c)rou, H.; MA(c)nez, J. F.; Berthou, F. Analysis of N-nitrosamines by high-performance liquid chromatography with post-column photo hydrolysis and colorimetric detection. J. Chromatogr. A., 1996, 727, 83-92.
[56]
Determination of NDMA in Valsartan Active Substances and Finished Products by HPLC/UV. Available from: www.ansm.sante.fr
[57]
Banerjee, S.; Mazumdar, S. Electrospray ionization mass spectrometry: A technique to access the information beyond the molecular weight of the analyte. Int. J. Anal. Chem., 2012, 2012, 1-40.
[http://dx.doi.org/10.1155/2012/282574] [PMID: 22611397]
[58]
Basics of LC/MS. Available from: https://www.agilent.com/cs/library/support/documents/a05296.pdf
[59]
Mass Spectrometry Ionization Methods. Available from: https://chemistry.emory.edu/msc/tutorial/mass-spectrometry-ionization-html
[60]
Sargent, M., Ed.;. Guide to Achieving Reliable Quantitative LC-MS Measurements, 1st ed.; RSC Analytical Methods Committee , 2013.
[61]
Lee, J.H. Analysis of nine nitrosamines in water by combining automated solid-phase extraction with high-performance liquid chromatography-atmospheric pressure ionization tandem mass spectrometry. Int. J. Environ. Anal. Chem., 2013, 93, 1261-1273.
[http://dx.doi.org/10.1080/03067319.2013.803281]
[62]
Lindholm, P.C.; Knuutinen, J.S.; Ahkola, H.S.J.; Herve, S.H. Analysis of pharmaceuticals. BioResources, 2014, 9, 3688-3732.
[http://dx.doi.org/10.15376/biores.9.2.3688-3732]
[63]
Topuz, E.; Aydin, E.; Pehlivanoglu-Mantas, E. A practical LC-MS/MS method for the detection of NDMA at nanogram per liter concentrations in multiple water matrices. Water Air Soil Pollut., 2012, 223(9), 5793-5802.
[http://dx.doi.org/10.1007/s11270-012-1315-1]
[64]
Zeilmaker, M.J.; Bakker, M.I.; Schothorst, R.; Slob, W. Risk assessment of N-nitrosodimethylamine formed endogenously after fish-with-vegetable meals. Toxicol. Sci., 2010, 116(1), 323-335.
[http://dx.doi.org/10.1093/toxsci/kfq093] [PMID: 20351056]
[65]
Scherf-Clavel, O.; Kinzig, M.; Besa, A.; Schreiber, A.; Bidmon, C.; Abdel-Tawab, M.; Wohlfart, J.; SArgel, F.; Holzgrabe, U. The contamination of valsartan and other sartans, Part 2: Untargeted screening reveals contamination with amides additionally to known nitrosamine impurities. J. Pharm. Biomed. Anal., 2019, 172, 278-284.
[http://dx.doi.org/10.1016/j.jpba.2019.04.035] [PMID: 31078064]
[66]
Guo, L.; Long, Z.; Leng, X. Rapid Analysis of Genotoxic Nitrosamines by HPLC-MS/MS Sensitive, Robust Assay Using a SCIEX Triple QuadTM 4500 System and the ExionLCTM System. 2019. Available from: https://sciex.com/content/dam/SCIEX/pdf/tech-notes/all/Rapid-Analysis-of-Genotoxic-Nitrosamines-by-HPLC-MS-MS.pdf
[67]
Roux, J.L.; Gallard, H.; CrouA(c), J.P.; Papot, S.; Deborde, M. NDMA formation by chloramination of ranitidine: Kinetics and mechanism. Environ. Sci. Technol., 2012, 46(20), 11095-11103.
[http://dx.doi.org/10.1021/es3023094] [PMID: 22967139]
[68]
Spahr, S.; Cirpka, O.A.; von Gunten, U.; Hofstetter, T.B. Formation of N -Nitrosodimethylamine during chloramination of secondary and tertiary amines: Role of molecular oxygen and radical intermediates. Environ. Sci. Technol., 2017, 51(1), 280-290.
[http://dx.doi.org/10.1021/acs.est.6b04780] [PMID: 27958701]
[69]
Jafvert, C.T.; Valentine, R.L. Reaction scheme for the chlorination of ammoniacal water. Environ. Sci. Technol., 1992, 26(3), 577-586.
[http://dx.doi.org/10.1021/es00027a022]
[70]
Hrudey, S.E.; Bull, R.J.; Cotruvo, J.A.; Paoli, G.; Wilson, M. Drinking water as a proportion of total human exposure to volatile N-nitrosamines. Risk Anal., 2013, 33(12), 2179-2208.
[http://dx.doi.org/10.1111/risa.12070] [PMID: 23786353]
[71]
Montesano, R.; Hall, J. Nitrosamine metabolism and carcinogenesis. In: Mutation, Cancer, and Malformation; Springer: Boston, MA, 1984; pp. 447-464.
[http://dx.doi.org/10.1007/978-1-4613-2399-0_21]
[72]
FDA Alert. FDA Updates on Angiotensin II Receptor Blocker (ARB) Recalls. Available from: www.fda.gov/drugs/drug-safety-and-availability/recalls-angiotensin-II-receptor-blockers-arbs-including-valsartan-losartan-and-irbesartan
[73]
Mirvish, S. S. Formation of n-nitroso compounds: Chemistry, kinetics, and in vivo occurrence. Toxicol. Appl. Pharmacol., 1975, 31, 325-351.
[74]
Spinco, B.; Dr. BM., Rao Nitrosamine Impurities: Current Regulatory Status".
[75]
Health Canada. Guidance on Nitrosamine Impurities in Medications, 2022.
[76]
Control of Nitrosamine impurities in Human Drugs, Guidance for Industry, 2021.

Rights & Permissions Print Cite
Article Metrics
51
2
Wayfinder Image
Open Access Journals Promotions
© 2024 Bentham Science Publishers | Privacy Policy